HCV Lifecycle Assay

HCV Lifecycle Assay

Viriome has access to the novel assay that allows identificiation of HCV drug candidates inhibiting an point in the HCV life cycle.

Need for an HCV Lifecycle Assay

Existing drugs inhibit only 2 targets in HCV: protease and polymerase activity

Discovering drugs with other mechanisms is limited by lack of robust cell culture models of HCV infection

Dr. Frank Chisari and Viriome have established an HCV cell-based infection system that can identify drug candidates at every step in the HCV life cycle

Already demonstrated that the system can identify known mechanisms, and compounds at multiple steps of the life cycle

•

Viriome Cell-based Screening

•

Screening in HCV life cycle assay for potency

Screening in the same assay for lack of cell toxicity

Mode of action analysis

Time of addition experiments

Efffect on HCV pseudotype entry inhibition
Effect on replicon cells
Effect on assembly-secretion rate
Effect on persistently infected cells

Viriome

The HCV Inhibitor Machine